Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous natural killer T cells (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous natural killer T (NKT) cells are an adoptive cell therapy being developed by the Chinese PLA General Hospital for the treatment of various advanced, treatment-refractory solid tumors. NKT cells represent a unique lineage of T cells that express both a semi-invariant T-cell receptor (TCR) and natural killer (NK) cell markers. These cells are characterized by their ability to recognize glycolipid antigens presented by the non-polymorphic MHC class I-like molecule CD1d. In this therapeutic approach, NKT cells are isolated from the patient's peripheral blood, expanded and activated ex vivo, and subsequently re-infused. Upon re-infusion, these cells exert anti-tumor effects through direct cytotoxicity and the rapid production of large quantities of Th1-type cytokines, such as interferon-gamma (IFN-γ), which further orchestrate and enhance the host's overall anti-tumor immune response by activating NK cells and CD8+ T cells.
- Other names
- autologous natural killer T cells-Chinese PLA General Hospital-breast cancer-glioma-hepatocellular carcinoma-squamous cell lung cancer-pancreatic cancer-colon cancer-prostate cancerAutologous NKT cellsNKT cell-based autologous adoptive immunotherapy
02
Targets
CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on autologous natural killer T cells (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous natural killer T cells (Chinese PLA General Hospital).